title: The ubiquitin-proteasome system and its potential application in hepatocellular carcinoma therapy.
abstract: The ubiquitin-proteasome system (UPS) is a complicated tightly controlled system in charge of degrading 80-90% of proteins, and is central to regulating cellular function and keeping protein homeostasis. Therefore, the components of UPS attract considerable attention as potential targets for hepatocellular carcinoma (HCC) therapy. The clinical success of bortezomib in multiple myeloma and mantle cell lymphoma patients has set the precedent for therapeutically targeting this pathway. This review will provide an overview of the UPS in HCC and the current status of therapeutic strategies.
authors.affiliation: Department of Gastroenterology, Zhongshan Hospital of Fudan University, Shanghai 200032, China; Shanghai Institute of Liver Diseases, Zhongshan Hospital of Fudan University, Shanghai 200032, China.
authors.forename: Yan-Jie
authors.initials: YJ
authors.lastname: Chen
authors.affiliation: Department of Gastroenterology, Zhongshan Hospital of Fudan University, Shanghai 200032, China; Shanghai Institute of Liver Diseases, Zhongshan Hospital of Fudan University, Shanghai 200032, China.
authors.forename: Hao
authors.initials: H
authors.lastname: Wu
authors.affiliation: Department of Gastroenterology, Zhongshan Hospital of Fudan University, Shanghai 200032, China; Shanghai Institute of Liver Diseases, Zhongshan Hospital of Fudan University, Shanghai 200032, China. Electronic address: shen.xizhong@zs-hospital.sh.cn.
authors.forename: Xi-Zhong
authors.initials: XZ
authors.lastname: Shen
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D000069286:Bortezomib / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000201:enzymology* / Q000473:pathology; D015195:Drug Design; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000201:enzymology* / Q000473:pathology; D058990:Molecular Targeted Therapy; D009842:Oligopeptides / Q000627:therapeutic use; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism*; D061988:Proteasome Inhibitors / Q000627:therapeutic use*; D011499:Protein Processing, Post-Translational / Q000187:drug effects*; D054875:Ubiquitination
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D009842:Oligopeptides; D061988:Proteasome Inhibitors; D000069286:Bortezomib; C524865:carfilzomib; D046988:Proteasome Endopeptidase Complex
keywords: Hepatocellular carcinoma; Inhibitor; Treatment; Ubiquitin–proteasome system